Saluda Medical Inc · ASX:SLD
Saluda Medical — Investor Presentation (October 2026)
13 slides from Saluda Medical's investor presentation, Oct 29, 2026
Slide 1: Saluda Medical FY27 Q1 Update
Saluda Medical FY27 Q1 Update October 29, 2026 Weare on a Mission to Transform Patients’ Lives with Revolutionary Neural-Sensing Technology
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer THIS DOCUMENT AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIB
Slide 3: Saluda's Value Proposition
Saluda’s Value Proposition Clinical differentiation converging into commercial and economic leverage PAIN RELIEF AT 36 MONTHS Durability 83% Most compelling long-term efficacy profile in SCS Zero explants for loss of efficacy in EVOKE clinical trial REPROGRAMMING VISITS PER YEAR Overcomes Reprogramm
Slide 4: Evoke System Stimulates, Measures and Adjusts Therapy on Every Pulse
Evoke® System Stimulates, Measures and Adjusts Therapy on Every Pulse Implanted lead delivers stimulation & measures resulting neural response, enabling personalised therapy Stimulate Individual optimal dose Patient A Pain relief starts with neural SCS activation leads Neural activation Sense and Me
Slide 5: Lower Reprogramming Rates | Real World Experience
Lower ReprogrammingRates | Real World Experience Commercial patients through June 2026 have less than one reprogramming visit after 12 months1 6.0 7 6.0 Visits per year, per Patient Average Visits2 with Standard SCS2 6 5 4 3.1 Average Visits <1 visit per year after the first 12 months S i g n i f i
Slide 6: EVA Automated Programming System Changes the Game
EVATM Automated Programming System Changes the Game Deep Data Analytics and Automation for Personalised Therapy 92% 96% Pain responder Patient (≥50% Pain relief)1 = 97% satisfaction1 000 67% Of Patients felt a Pain high responder Analysethe Find the DeterminePersonalised sense of control1 (≥80% Pain
Slide 7: Q1 FY27 Quarterly Activity Report
Q1 FY27 Quarterly Activity Report ASX announcement highlights Q1 Q1 Growth ▪ Global revenue of US$23.1 million, +26% vs prior corresponding FY27 FY26 vs. PCP period (pcp), reflecting continued commercial momentum. US Revenue ($m) 17.4 12.9 34% ▪ Quarterly US patient implants of 838, +55% vs pcp, sup
Slide 8: Q1 FY27 Quarterly Activity Report
Q1 FY27 Quarterly Activity Report Revenue and select US commercial metrics QUARTERLY REVENUE TREND (US$M) 1 QUARTERLY US COMMERCIAL METRICS 1 900.0 ASX IPO $27.0M US Implanted Patients US Avg Qtrly Active Physicians 838 800.0 US Int'l 769 $23.8M 700.0 $23.1M 8.5 3 3 695 $21.0M 670 600.0 $18.9M 7.4 2
Slide 9: FY27 Guidance Reaffirmed
FY27 Guidance Reaffirmed Full-year guidance ranges unchanged from the year-end release FY27 GUIDANCE Q1 COMMERCIAL PROGRESS US$ millions, except margin FY27 range Change Y/Y +55% US patient implants 838 in Q1 FY27 Revenue $113 – $122 +25% – 35% +47% US active physicians 374 quarterly average Gross m
Slide 10: Strong Market Adoption with Key Future Growth Drivers
1 Strong Market Adoption with Key Future Growth Drivers Evoke® System gaining market share with positive momentum since launch REVENUE PROFILE (US$M) 1 KEY GROWTH DRIVERS Growth in key metrics – well positioned to continue expansion into FY27 and beyond +30% CAGR $113-$122 Expand into New ▪ <30% US
Slide 11: Paddle Lead: Entering the Orthopedic / Neurosurgeon Market
Expand into New Expand Within Launch Enter New Territories Existing Physicians New Products Channels Paddle Lead: Entering the Orthopedic / Neurosurgeon Market O RT H O / N E U RO S U RG E O N S : 3 0 % O F U.S . M A R K E T 2 PADDLE LAUNCH Competitive Early stage of LAUNCH UNDERWAY replacements an
Slide 12: Why Saluda Is Different
Why Saluda Is Different Solving structural barriers that have limited SCS adoption and profitability THE TWO BIGGEST PROBLEMS IN SCS THE SALUDA ANSWER 1 Durability of outcomes Outcomes that hold up over time Effectiveness fades — driving reprogramming & attrition 83% 90% ZERO RESPONDER RATE DURABILI
Slide 13: This Changes Everything.
EVERYTHING CHANGES. THIS CHANGES EVERYTHING. Therapy as Dynamic as Life.
Saluda Medical — Investor Presentation (October 2026) on 6ix